The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PVLA | N/A | N/A | N/A | +486% |
| S&P | +18.13% | +110.72% | +16.08% | +13% |
Develops and markets an anticalin-brand protein technology
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Gross Margin | 156.60% | 0.0% |
| Market Cap | $249.20M | 0.0% |
| Market Cap / Employee | $4.98M | 0.0% |
| Employees | 50 | 0.0% |
| Net Income | -$9.47M | -163.8% |
| EBITDA | -$9.25M | -121.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $70.43M | 257.0% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $14.51M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -39.93% | 0.0% |
| Return On Invested Capital | 38.30% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.43M | -267.2% |
| Operating Free Cash Flow | -$5.43M | -267.2% |
| Metric | Q1 2025 | Q2 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Book | 2.27 | 4.47 | - | ||
| Price to Sales | 0.42 | 0.44 | 0.61 | 16.19 | - |
| Price to Tangible Book Value | 2.27 | 4.47 | - | ||
| Enterprise Value to EBITDA | 1.67 | -0.80 | -29.56 | -20.89 | -11769.49% |
| Return on Equity | -89.8% | -86.9% | -80.5% | -68.2% | - |
| Total Debt | $0.00M | $0.00M | $0.00M | $14.51M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
